N4 Pharma PLC (GB:THAT)
LSE:THAT
THAT Stock Chart & Stats
0.60 p
<0.01 p(0.80%)
At close: 4:00 PM EST
0.60 p
<0.01 p(0.80%)
Day’s Range― - ―
52-Week Range0.35 p - 1.00 p
Previous CloseN/A
VolumeN/A
Average Volume (3M)552.75K
Market Cap
£3.75M
Enterprise Value3.89M
Total Cash (Recent Filing)£1.73M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding832,280,330
10 Day Avg. Volume400,768
30 Day Avg. Volume552,755
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.76
Price to Sales (P/S)245.40
P/FCF Ratio-1.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
THAT FAQ
What was N4 Pharma PLC’s price range in the past 12 months?
N4 Pharma PLC lowest share price was 0.35 p and its highest was 1.00 p in the past 12 months.
What is N4 Pharma PLC’s market cap?
N4 Pharma PLC’s market cap is £3.75M.
When is N4 Pharma PLC’s upcoming earnings report date?
N4 Pharma PLC’s upcoming earnings report date is Sep 24, 2026 which is in 163 days.
How were N4 Pharma PLC’s earnings last quarter?
Currently, no data Available
Is N4 Pharma PLC overvalued?
According to Wall Street analysts N4 Pharma PLC’s price is currently Overvalued.
Does N4 Pharma PLC pay dividends?
N4 Pharma PLC does not currently pay dividends.
What is N4 Pharma PLC’s EPS estimate?
N4 Pharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does N4 Pharma PLC have?
N4 Pharma PLC has 832,280,330 shares outstanding.
What happened to N4 Pharma PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of N4 Pharma PLC?
Currently, no hedge funds are holding shares in GB:THAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
N4 Pharma PLC
Thalia Therapeutics Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-clinical development for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring. Thalia Therapeutics Plc was formerly known as N4 Pharma Plc and changed its name to Thalia Therapeutics Plc in March 2026. Thalia Therapeutics Plc was incorporated in 1979 and is based in Chellaston, the United Kingdom.
Technical Analysis
Eco Animal Health
―
Chill Brands Group PLC
―
Mountfield
―
Provexis
―
Shield Therapeutics
―